BioCentury | Jul 30, 2020
Deals

UCB deal gives Roche a second shot on goal with tau in Alzheimer’s

...pursuit. Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit will gain exclusive, global rights to UCB0107...
...tau pathology. Subsequently, Genentech can choose to continue clinical development or return rights to UCB. UCB0107...
...tau program in Alzheimer’s disease. Targets tau (MAPT; FTDP-17) - Microtubule-associated protein tau Sandi Wong, Assistant Editor UCB0107 UCB...
Items per page:
1 - 1 of 1